Akero Therapeutics, Inc.
akerotx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 7, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Nov 7, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops efruxifermin, an investigational treatment for a serious metabolic liver disease, for patients with liver scarring or cirrhosis.
10-K for FY2024, filed Feb 28, 2025
How Did They Make Money?
No revenue was reported.
10-K for FY2024, filed Feb 28, 2025
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 7, 2025
−$81.6MView ↗
- ▲ +12% (Loss)
- vs −$72.7M in Q3 FY2024
-
Dec 9, 2025
Novo Nordisk completed its acquisition of Akero
Akero became a wholly owned subsidiary; trading in its shares was suspended ahead of delisting.
Sources
8-K, filed Dec 9, 2025
As a result of the consummation of the Merger, there was a change in control of the Company, and the Company became a wholly owned…View ↗
Who Did They Compete With?
Competes with Boehringer Ingelheim, Eisai, Eli Lilly, GSK, Johnson & Johnson, Merck &, Novo Nordisk, Pfizer, Takeda Pharmaceutical, Aligos Therapeutics, Alnylam Pharmaceuticals, Altimmune, Amgen, Arrowhead Pharmaceuticals, Boston Pharmaceuticals, Cirius Therapeutics, Corcept Therapeutics, D&D Pharmatech, Eccogene, and 89bio
10-K for FY2024, filed Feb 28, 2025We understand that a number of pharmaceutical companies, including AstraZeneca PLC/MedImmune LLC, Boehringer Ingelheim AG, Eisai, Inc., Eli…View ↗
Loading...
